All In Biotech

Drug Trial Radar · NCT01613846

Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)

Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Apr 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 544 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

544

Planned (sponsor's estimate)

Start

May 2012

Primary completion

Oct 30, 2016

Sponsor

Lead sponsor
Technical University of MunichAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 7, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Sorafenib and pazopanib are both effective and promising treatments for advanced Renal Cell Carcinoma (RCC). Both drugs are registered for this indication. No prospective comparative data in advanced RCC (or other indications) have been published. A search in the clinicaltrials.gov database did not reveal any planned or ongoing studies. As sequential therapy is now the standard of treatment for advanced RCC it is important to evaluate in clinical trials what the value of different sequential strategies is. This needs to be done every time new agents are introduced into the treatment armamentarium. As there are no data yet on the sequential use of sorafenib followed by pazopanib or vice versa, this sequence, however, will most certainly be used in daily practice, it is required to examine efficacy and safety of this sequential approach in a clinical trial in a randomized setting. Therefore, the investigators have designed an open randomized study in patients not previously treated for advanced RCC. Suitable patients will be randomized (1:1) in 2 groups.

Conditions

  • Renal Cell Carcinoma

Interventions

  • Sorafenib+PazopanibDrug

    Sorafenib (first-line) followed by Pazopanib (second-line)

  • Pazopanib+SorafenibDrug

    Pazopanib (first-line) followed by Sorafenib (second-line)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate if progression-free survival from randomization to progression or death during second-line therapy (Total PFS) of sorafenib followed by pazopanib is non-inferior compared to pazopanib followed by sorafenib.Time frame: 4 years

Locations

72 sites in 3 countries. Site status is shown where the registry gives one.

  • Medizinische Universität Innsbruck

    Innsbruck, Austria

  • A. ö. Bezirkskrankenhaus Kufstein

    Kufstein, Austria

  • AKH Linz GmbH

    Linz, Austria

  • LKH Salzburg

    Salzburg, Austria

  • Universitätsklinikum Aachen, Urologische Klinik

    Aachen, Germany

  • Gesundheitszentrum St. Marien GmbH

    Amberg, Germany

  • Praxis für Urologie

    Berlin, Germany

  • Charite Campus Virchow Klinikum / Klein. Für Innere Med / Onkologie/Hämatologie

    Berlin, Germany

  • Gemeinschaftspraxis Pott / Tirier / Hannig - Onkologie

    Bottrop, Germany

  • Urologie im Schlosscarrée Braunschweig

    Braunschweig, Germany

  • Klinikum Bremen-Mitte gGmbH

    Bremen, Germany

  • Bethanien Krankenhaus Chemnitz gGmbH

    Chemnitz, Germany

  • Überörtliche Gemeinschaftspraxis

    Cologne, Germany

  • Onkologische Gemeinschaftspraxis Dörfel/Göhler

    Dresden, Germany

  • Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden

    Dresden, Germany

  • Urologische Gemeinschaftspraxis

    Duisburg, Germany

  • Krankenhaus Düren gGmbH

    Düren, Germany

  • Universitätsklinikum Düsseldorf

    Düsseldorf, Germany

  • Urologische Facharztpraxis

    Eisleben Lutherstadt, Germany

  • Urologie Neandertal - Ortsübergreifende Gemeinschaftspraxis für Urologie

    Erkrath, Germany

  • Waldkrankenhaus St. Marien

    Erlangen, Germany

  • St.-Antonius-Hospital in Eschweiler / Klinik f. Hämatologie und Onkologie

    Eschweiler, Germany

  • Hämato-onkologische Gemeinschaftspraxis

    Essen, Germany

  • Onkozentrum Freiberg

    Freiberg, Germany

  • Praxis für interdisziplinäre Onkologie & Hämatologie

    Freiburg im Breisgau, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • MVZ Osthessen GmbH

    Fulda, Germany

  • Gem.praxis Dres. J. Wilke, H. Wagner - Hämatol.u.intern.Onkol. am Klinikum Fürth

    Fürth, Germany

  • Onkologische Schwerpunktpraxis

    Goslar, Germany

  • Universitätsklinikum Göttingen

    Göttingen, Germany

  • Universitätsmedizin Greifswald

    Greifswald, Germany

  • St. Antonius-Hospital Gronau GmbH

    Gronau, Germany

  • Onkologische Schwerpunktpraxis

    Hamburg, Germany

  • Asklepios Klinik Altona

    Hamburg, Germany

  • Universitätsklinikum Heidelberg, Klinik für Urologie

    Heidelberg, Germany

  • Urologie-Heinsberg

    Heinsberg, Germany

  • Onkologische Praxis

    Hildesheim, Germany

  • Universitätsklinikum des Saarlandes

    Homburg, Germany

  • Universitätsklinikum Jena, Klinik für Urologie

    Jena, Germany

  • Praxis für Urologie

    Lauenburg, Germany

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.